AR069407A1 - Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos - Google Patents
Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usosInfo
- Publication number
- AR069407A1 AR069407A1 ARP080105077A ARP080105077A AR069407A1 AR 069407 A1 AR069407 A1 AR 069407A1 AR P080105077 A ARP080105077 A AR P080105077A AR P080105077 A ARP080105077 A AR P080105077A AR 069407 A1 AR069407 A1 AR 069407A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- arg
- dichloro
- yloxymethyl
- igi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Reivindicacion 1: Composiciones farmacéuticas, caracterizadas porque comprenden, como ingredientes activos, una mezcla de: a) ácido hialuronico o sus sales seleccionadas de sodio y potasio; b) un antagonista del receptor de bradiquinina B2 junto con portadores y excipientes farmacéuticamente aceptables, en donde: el ácido hialuronico está en forma polimérica con un PM medio entre 0,5 y 10 millones de dalton, y el antagonista de bradiquinina se selecciona de: antagonistas del receptor B2, seleccionados del grupo de: H-D-Arg-Arg-Pro-Hyp-Gly-IgI-Ser-D-F5F-IgI-Arg-OH, H-Arg-Arg-Pro-Hyp-Gly-IgI-Ser-D-IgI-Oic-Arg-OH, H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (Icatibant); 4-[2-[([[3-(3-Brom-2-metilo-imidazo[1,2-a]piridina-8-iloximetil)-2,4-dicloro-fenil]-metilo-carbamoil]-metilo)-carbamoil]-vinil]-N,N-dimetil-benzamida, 3-(6-Acetilamino-piridina-3-il)-N-([[2,4-dicloro-3-(2-metilo-quinoline-8-iloximetil)-fenil]-metilo-carbamoil]-metilo)-acrilamida, [3-(4-carbamidoil-benzoilamino)-propil]-amida del ácido 1-[2,4-Dicloro-3-(2,4-dimetil-quinolin-8-iloximetil)-bencensulfonil-pirrolidin-2-carboxílico (Anatibant); 4-(4--[1-[2,4-Dicloro-3-(2,4-dimetil-quinolin-8-iloximetil-bencensulfonil]-pirrolidina-2-carbonil]-piperazin-1-carbonil)-benzamidina, 2-[5-(4-Ciano-benzoil)-1-metilo-1H-pirrol-2-il]-N-[2,4-dicloro-3-(2-metilo-quinolin-8-iloximetil)-fenil]-N-metilo-acetamida, antagonistas del receptor B2, que tienen la formula general (1) en donde R es hidrogeno o metilo, W representa un enlace simple o un átomo de O, n = 3, 4, X es hidrogeno o un grupo amino -NR1R2, en el que R1 y R2 pueden ser de modo independiente entre sí hidrogeno o un grupo seleccionado de metilo, etilo, n-propilo, isopropilo, Y es un amonio cuaternario (-NR3R4R5)+A- en el que R3, R4, R5 pueden ser de modo independiente entre sí metilo, etilo, n-propilo, isopropilo, butilo, isobutilo, n-pentilo y A- es un anion de un ácido farmacéuticamente aceptable; sus sales, enantiomeros y mezclas enantioméricas farmacologicamente aceptables. Reivindicacion 17: El uso del ácido hialuronico en asociacion con un antagonista del receptor de bradiquinina B2 para la preparacion de las composiciones farmacéuticas de acuerdo con la reivindicacion 1, para la profilaxis y el tratamiento de enfermedades articulares inflamatorias, autoinmunes, traumáticas y degenerativas tales como osteoartritis y osteoartritis postraumática, osteoartritis degenerativa (gonartritis, espondilartritis), espondilosis, sinovitis, tenosinovitis, bursitis, contusiones, esguinces, luxaciones y subluxaciones, y en enfermedades articulares causados por alteraciones de desarrollo tales como osteocondritis y displasia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002225A ITMI20072225A1 (it) | 2007-11-23 | 2007-11-23 | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069407A1 true AR069407A1 (es) | 2010-01-20 |
Family
ID=40314753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105077A AR069407A1 (es) | 2007-11-23 | 2008-11-21 | Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos |
Country Status (41)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3153156A4 (en) * | 2014-05-30 | 2018-02-14 | Derkach, Nataliia Mykolaivna | Composition based on a stabilized solution of active ingredients |
| JP6864948B2 (ja) | 2014-12-26 | 2021-04-28 | 生化学工業株式会社 | 眼の自覚症状を改善する剤および方法 |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
| ITMI20021247A1 (it) * | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
-
2007
- 2007-11-23 IT IT002225A patent/ITMI20072225A1/it unknown
-
2008
- 2008-11-07 TW TW097142981A patent/TWI448292B/zh not_active IP Right Cessation
- 2008-11-10 AP AP2010005265A patent/AP2628A/xx active
- 2008-11-10 UA UAA201006127A patent/UA97867C2/ru unknown
- 2008-11-10 AT AT08853047T patent/ATE529096T1/de active
- 2008-11-10 AU AU2008328311A patent/AU2008328311B2/en not_active Ceased
- 2008-11-10 GE GEAP200811807A patent/GEP20125602B/en unknown
- 2008-11-10 PL PL08853047T patent/PL2222275T3/pl unknown
- 2008-11-10 EP EP08853047A patent/EP2222275B1/en active Active
- 2008-11-10 RS RS20110524A patent/RS52045B/en unknown
- 2008-11-10 ES ES08853047T patent/ES2374861T3/es active Active
- 2008-11-10 BR BRPI0820402-0A patent/BRPI0820402A2/pt not_active IP Right Cessation
- 2008-11-10 US US12/743,891 patent/US9101627B2/en not_active Expired - Fee Related
- 2008-11-10 JP JP2010534395A patent/JP5383695B2/ja not_active Expired - Fee Related
- 2008-11-10 CN CN2008801169202A patent/CN101868225B/zh not_active Expired - Fee Related
- 2008-11-10 MY MYPI2010002358A patent/MY148685A/en unknown
- 2008-11-10 SI SI200830475T patent/SI2222275T1/sl unknown
- 2008-11-10 EA EA201000678A patent/EA017626B1/ru not_active IP Right Cessation
- 2008-11-10 WO PCT/EP2008/009451 patent/WO2009065507A2/en active Application Filing
- 2008-11-10 NZ NZ585514A patent/NZ585514A/en not_active IP Right Cessation
- 2008-11-10 CA CA2706398A patent/CA2706398C/en not_active Expired - Fee Related
- 2008-11-10 PT PT08853047T patent/PT2222275E/pt unknown
- 2008-11-10 KR KR1020107011164A patent/KR101585868B1/ko not_active IP Right Cessation
- 2008-11-10 DK DK08853047.2T patent/DK2222275T3/da active
- 2008-11-10 MX MX2010005484A patent/MX2010005484A/es active IP Right Grant
- 2008-11-19 PE PE2008001955A patent/PE20091422A1/es not_active Application Discontinuation
- 2008-11-21 AR ARP080105077A patent/AR069407A1/es unknown
- 2008-11-21 CL CL2008003475A patent/CL2008003475A1/es unknown
- 2008-11-21 PA PA20088804801A patent/PA8804801A1/es unknown
-
2010
- 2010-05-05 EC EC2010010153A patent/ECSP10010153A/es unknown
- 2010-05-06 CO CO10054082A patent/CO6270301A2/es active IP Right Grant
- 2010-05-14 TN TN2010000215A patent/TN2010000215A1/fr unknown
- 2010-05-19 NI NI201000087A patent/NI201000087A/es unknown
- 2010-05-20 HN HN2010001037A patent/HN2010001037A/es unknown
- 2010-05-20 ZA ZA2010/03586A patent/ZA201003586B/en unknown
- 2010-05-20 IL IL205860A patent/IL205860A/en not_active IP Right Cessation
- 2010-05-21 CR CR11457A patent/CR11457A/es unknown
- 2010-06-15 MA MA32913A patent/MA31913B1/fr unknown
-
2011
- 2011-04-19 HK HK11103946.6A patent/HK1149714A1/xx not_active IP Right Cessation
- 2011-11-30 CY CY20111101177T patent/CY1112134T1/el unknown
- 2011-12-02 HR HR20110904T patent/HRP20110904T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
| NZ595759A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| UA110310C2 (uk) | Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar) | |
| HRP20130935T1 (hr) | Bicikliäśki derivat aminokiseline | |
| NZ590784A (en) | Pyrazolopyridine kinase inhibitors | |
| US20150196540A1 (en) | Nmda receptor modulators and uses related thereto | |
| AR069407A1 (es) | Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos | |
| CO6251286A2 (es) | Sales amino del acido [4, 6-bis(dimetilamino)-2-(4-(4-trifluorometil)benzamido)bencil)pirimidin-5-il]acetico, composiciones farmaceuticas de las mismas y sus usos para el tratamiento de enfermedades mediadas por crth-2 | |
| CY1124329T1 (el) | N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων | |
| EA201691538A1 (ru) | Способ получения солей вортиоксетина | |
| MA32564B1 (fr) | NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| PE20090839A1 (es) | Derivados de isoxazol-imidazol | |
| HRP20110624T1 (hr) | Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 | |
| NZ600266A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| JP5208963B2 (ja) | キマーゼ阻害剤としてのスルホンアミド誘導体 | |
| RU2008129623A (ru) | Ингибиторы ccr9 активности | |
| EA202092955A1 (ru) | Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза | |
| MX2022004215A (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4. | |
| JP2011529936A5 (es) | ||
| US20160310511A1 (en) | Myxovirus Therapeutics, Compounds, and Uses Related Thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |